Absorption Rate Limit Considerations for Oral Phosphate Prodrugs

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2003 Jun 24

PMID 12817887

Citations 16

Authors

Tycho Heimbach

Doo-Man Oh

Lilian Y Li

Markus Forsberg

Jouko Savolainen

Jukka Leppanen

Yasushi Matsunaga

Gordon Flynn

David Fleisher

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the potential of phosphate ester prodrugs to significantly improve the absorptive flux of poorly soluble parent drugs.

Methods: Absorptive transport studies of parent drugs and their prodrugs were carried out in Caco-2 cells. Prodrugs of parent drugs with variable aqueous solubilities were tested: Hydrocortisone-phosphate/Hydrocortisone, Fosphenytoin/phenytoin, TAT-59/DP-TAT-59, and Entacapone phosphate/Entacapone. Additional absorption studies were carried out in rats.

Results: Absorptive fluxes of DP-TAT-59 and phenytoin increased 9.8 or 3.3-fold after dosing TAT-59 and 500 microM fosphenytoin, respectively. Hydrocortisone's flux did not increase with hydrocortisone-phosphate at 100 microM. Permeability of the highly lipophilic and protein bound compound, DP-TAT-59, was significantly increased with serosal albumin. No permeability increase was observed for the other drugs with albumin. Entacapone phosphate failed to improve the flux of entacapone compared to an entacapone solution, but the prodrug solution did yield higher entacapone plasma levels in rats when compared with an entacapone suspension.

Conclusion: Ideal phosphate prodrug candidates are characterized by high permeability and low solubility (BCS Class II drugs). For low dose BCS Class II drug candidates, however, no biopharmaceutical advantage may be gained. Phosphate prodrugs of parent drugs with limited permeability may fail. When screening highly lipophilic parent drugs transport studies should be done with albumin.

Citing Articles

Sol-moiety: Discovery of a water-soluble prodrug technology for enhanced oral bioavailability of insoluble therapeutics.

Karbasi A, Barfuss J, Morgan T, Collins D, Costenbader D, Dennis D Nat Commun. 2024; 15(1):8487.

PMID: 39353935 PMC: 11445516. DOI: 10.1038/s41467-024-52793-6.

Encapsulation and release of hydrocortisone from proliposomes govern vaginal delivery.

Mast M, Mesquita L, Gan K, Gelperina S, das Neves J, Wacker M Drug Deliv Transl Res. 2022; 13(4):1022-1034.

PMID: 36585558 DOI: 10.1007/s13346-022-01263-x.

The evolution of nucleosidic analogues: self-assembly of prodrugs into nanoparticles for cancer drug delivery.

Baroud M, Lepeltier E, Thepot S, El-Makhour Y, Duval O Nanoscale Adv. 2022; 3(8):2157-2179.

PMID: 36133769 PMC: 9418958. DOI: 10.1039/d0na01084g.

Discovery of Orally Bioavailable and Brain-Penetrable Prodrugs of the Potent nSMase2 Inhibitor DPTIP.

Pal A, Gori S, Yoo S, Thomas A, Wu Y, Friedman J J Med Chem. 2022; 65(16):11111-11125.

PMID: 35930706 PMC: 9980655. DOI: 10.1021/acs.jmedchem.2c00562.

Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir.

Wang T, Kadow J, Meanwell N Med Chem Res. 2021; 30(11):1955-1980.

PMID: 34602806 PMC: 8476988. DOI: 10.1007/s00044-021-02787-6.

References

Olivesi A . Oral prednisolone-21-phosphate is absorbed at the same rate and to the same extent as oral prednisolone in normal adults. Therapie. 1985; 40(1):1-4. View

Nomura Y, Abe O, Enomoto K, Fujiwara K, Tominaga T, Hayashi K . [Phase I study of TAT-59 (a new antiestrogen) in breast cancer. TAT-59 Study Group]. Gan To Kagaku Ryoho. 1998; 25(4):553-61. View

Kearney A, Stella V . Hydrolysis of pharmaceutically relevant phosphate monoester monoanions: correlation to an established structure-reactivity relationship. J Pharm Sci. 1993; 82(1):69-72. DOI: 10.1002/jps.2600820115. View

Burstein A, Cox D, Mistry B, Eddington N . Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats. Epilepsy Res. 1999; 34(2-3):129-33. DOI: 10.1016/s0920-1211(98)00107-7. View

Amidon G, Lennernas H, Shah V, Crison J . A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12(3):413-20. DOI: 10.1023/a:1016212804288. View

Rohdewald P, Mollmann H, Barth J, Rehder J, Derendorf H . Pharmacokinetics of dexamethasone and its phosphate ester. Biopharm Drug Dispos. 1987; 8(3):205-12. DOI: 10.1002/bdd.2510080302. View

Li C, Fleisher D, Li L, Schwier J, Sweetana S, Vasudevan V . Regional-dependent intestinal absorption and meal composition effects on systemic availability of LY303366, a lipopeptide antifungal agent, in dogs. J Pharm Sci. 2000; 90(1):47-57. DOI: 10.1002/1520-6017(200101)90:1<47::aid-jps6>3.0.co;2-2. View

Palm K, Luthman K, Ros J, Grasjo J, Artursson P . Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. J Pharmacol Exp Ther. 1999; 291(2):435-43. View

Fleisher D, Sheth N, Griffin H, McFadden M, Aspacher G . Nutrient influences on rat intestinal phenytoin uptake. Pharm Res. 1989; 6(4):332-7. DOI: 10.1023/a:1015906726365. View

10.

Savolainen J, Leppanen J, Forsberg M, Taipale H, Nevalainen T, Huuskonen J . Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone. Life Sci. 2000; 67(2):205-16. DOI: 10.1016/s0024-3205(00)00615-9. View

11.

Hande K . Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1999; 34(10):1514-21. DOI: 10.1016/s0959-8049(98)00228-7. View

12.

Heimbach T, Oh D, Li L, Forsberg M, Savolainen J, Leppanen J . Absorption rate limit considerations for oral phosphate prodrugs. Pharm Res. 2003; 20(6):848-56. DOI: 10.1023/a:1023827017224. View

13.

Chong B, Mersfelder T . Entacapone. Ann Pharmacother. 2000; 34(9):1056-65. DOI: 10.1345/aph.19328. View

14.

Leppanen J, Huuskonen J, Savolainen J, Nevalainen T, Taipale H, Vepsalainen J . Synthesis of a water-soluble prodrug of entacapone. Bioorg Med Chem Lett. 2000; 10(17):1967-9. DOI: 10.1016/s0960-894x(00)00384-x. View

15.

Sietsema W . The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol. 1989; 27(4):179-211. View

16.

Boogaerts M, Van Hoof A, Catovsky D, Kovacs M, Montillo M, Zinzani P . Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2001; 19(22):4252-8. DOI: 10.1200/JCO.2001.19.22.4252. View

17.

van Asten P, Duursma S, GLERUM J, Ververs F, van Rijn H, van Dijk A . Absolute bioavailability of fluoride from disodium monofluorophosphate and enteric-coated sodium fluoride tablets. Eur J Clin Pharmacol. 1996; 50(4):321-6. DOI: 10.1007/s002280050116. View

18.

Amidon G, Leesman G, Elliott R . Improving intestinal absorption of water-insoluble compounds: a membrane metabolism strategy. J Pharm Sci. 1980; 69(12):1363-8. DOI: 10.1002/jps.2600691203. View

19.

Kearney A, Stella V . The in vitro enzymic labilities of chemically distinct phosphomonoester prodrugs. Pharm Res. 1992; 9(4):497-503. DOI: 10.1023/a:1015840329786. View

20.

Wils P, Warnery A, Legrain S, Scherman D . High lipophilicity decreases drug transport across intestinal epithelial cells. J Pharmacol Exp Ther. 1994; 269(2):654-8. View